sorafenib has been researched along with 3-deazaneplanocin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (3-deazaneplanocin) | Trials (3-deazaneplanocin) | Recent Studies (post-2010) (3-deazaneplanocin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 161 | 0 | 136 |
| Protein | Taxonomy | sorafenib (IC50) | 3-deazaneplanocin (IC50) |
|---|---|---|---|
| Adenosylhomocysteinase | Homo sapiens (human) | 0.44 | |
| Histone-lysine N-methyltransferase EZH2 | Homo sapiens (human) | 0.08 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsiao, HH; Liu, TP; Lo, HL; Wei, LS; Yang, PM | 1 |
1 other study(ies) available for sorafenib and 3-deazaneplanocin
| Article | Year |
|---|---|
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Survival; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Knockdown Techniques; Hep G2 Cells; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Indazoles; Niacinamide; Phenylurea Compounds; Polycomb Repressive Complex 2; Pyridones; S-Adenosylmethionine; Sorafenib | 2015 |